Apnimed Completes Oversubscribed $79.75 Million Series C To Extension Financing
Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has raised $79.75 million in an oversubscribed financing round, bringing its total Series C funding to $142.25 million. Alpha Wave Ventures led the funding, which also included current investors … Read more